Active HIV Research Studies

About this Site

This website hosts a collection of HIV and HIV-related research at the University of California San Diego and affiliated sites. Progress in treatment for HIV, hepatitis C, hepatitis B, tuberculosis, and other related conditions only occurs with the valuable contributions of individuals who enroll in research studies. These clinical research trials help improve the treatment and management of HIV and other infections. 

We encourage you to bookmark this page and check back often, as new opportunities to participate in HIV and related research are added frequently. 

This site is managed by The HIV Institute at the University of California San Diego. Contact us at hiv@ucsd.edu with any questions, feedback, or recommendations. Please note, inquiries regarding a specific study or sponsoring center should be directed to the contact listed. The HIV Institute does not manage any of these studies.

To see all HIV/AIDS clinical trials at UC San Diego (including those in progress as well as actively enrolling studies), please visit the UC San Diego Health Clinical Trials page.

If you are interested in including a research opportunity on this page, please click the button below to submit details.

Submit studies


Disclaimer: Each sponsoring center and/or principal investigator is responsible for the studies listed on this website. This includes study preparation, conduct, and administration of a research grant, cooperative agreement, training or public service project, contract, or other sponsored project in compliance with applicable laws and regulations and institutional policy governing the conduct of sponsored research. Contact the indicated party listed below with any study-related questions.


Other UC San Diego HIV Research Studies

LinkPositively Study

 

Summary: The goal of this study is to assess feasibility and acceptability and determine preliminary effects of Linkpositively, a culturally-tailored and trauma-informed smartphone app, on HIV care outcomes (i.e., retention in care, ART adherence, viral suppression) and mechanism of change variables (i.e., social support, self-efficacy). Participants will be randomly assigned to either the intervention (LinkPositively smartphone app, n=40) or control (Ryan White standard of care, n=40) arm, with follow-up at 3- and 6- months. Participants assigned to LinkPositively will complete 5 one-on-one weekly virtual sessions with a peer navigator and engage with components of the LinkPositively app (i.e., social networking, resource locator, medication monitoring, educational tips) for a 6-month period. View enrollment flyer

Enrollment: Now through 8/1/2022

Contact: Alexandra Fernandez DeSoto; Email: alf013@health.ucsd.edu

Click here for more information and eligibility requirements

HIV


Live Healthy Study

 

Summary: If you are in HIV care and smoke or have recently quit, join the Live Healthy Study! This is a one-time survey on smoking status, physical & mental health, and social support. Survey takes 20-40 minutes & can be completed online, by phone, or in person. Compensation is a $30 Visa gift card.

Enrollment: Now through March 2022

Contact: Kimberly Brouwer at livehealthy@health.ucsd.edu

Click here for more information and eligibility requirements.

HIV


 

Summary: The purpose of this study is to evaluate the efficacy of a targeted therapy, loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemotherapy in persons with relapsed/refractory diffuse large B cell lymphoma.

Enrollment: Now through 2023

Contact: Erin Reid, MD at egreid@ucsd.edu

Click her for more information and eligibility requirements

HIV CANCER


AMC-083: Collecting and Studying Tissue Samples From Patients With HIV-Associated Malignancies

 

Summary: Collecting and studying tissue samples from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. This research trial is collecting tissue samples specifically from patients with HIV-related malignancies to study clinical, genetic, and immunologic parameters that have prognostic significance and/or are involved in the initiation and progression of HIV-1 malignancies, including complete genomic sequence determination of HIV-associated diffuse large B-cell lymphomas, lung cancer, anal cancer, and cervical cancer. 

Enrollment: now through December 2024

Contact: Erin Reid, MD at egreid@ucsd.edu

Click her for more information and eligibility requirements.

HIV CANCER


AMC-097: Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant

 

This phase I/II trial studies the side effects and best dose of gene therapy in treating patients with human immunodeficiency virus (HIV)-related lymphoma that did not respond to therapy or came back after an original response, who are planned to undergo stem cell transplant. In gene therapy, small stretches of deoxyribonucleic acid (DNA) called "anti-HIV genes" are introduced into the stem cells in the laboratory to make the gene therapy product used in this study. The type of anti-HIV genes and therapy in this study may make the patient's immune cells more resistant to HIV-1 and prevent new immune cells from getting infected with HIV-1.

Enrollment: now through December 2023.

Contact: Ayad Hamden, MD ayhamdan@health.ucsd.edu

Click here for more information and eligibility requirements.

HIV CANCER


AMC-101: Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

 

This phase I-II trial studies the side effects and best dose of ibrutinib in combination with rituximab, etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride in treating patients with human immunodeficiency virus (HIV)-positive stage II-IV diffuse large B-cell lymphomas. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as rituximab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ibrutinib and etoposide, prednisone, vincristine sulfate, cyclophosphamide, and doxorubicin hydrochloride may work better in treating patients with HIV-positive diffuse large B-cell lymphomas. 

Enrollment: now through December 2024. 

Contact: Erin Reid, MD egreid@ucsd.edu

Click her for more information and eligibility requirements.

HIV CANCER


AMC-095: Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery

 

This phase I trial studies the side effects and best dose of nivolumab when given with ipilimumab in treating patients with human immunodeficiency virus (HIV) associated solid tumors have spread to other places in the body or cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may block tumor growth in different ways by targeting certain cells. Ipilimumab is an antibody that acts against a molecule called cytotoxic T-lymphocyte antigen 4 (CTLA-4). CTLA-4 controls a part of your immune system by shutting it down. Nivolumab is a type of antibody that is specific for human programmed cell death 1 (PD-1), a protein that is responsible for destruction of immune cells. Giving ipilimumab with nivolumab may work better in treating patients with HIV associated solid tumors. 

Enrollment: now through December 2023.

Contact: William Wachsman, MD/PhD, wwachsman@ucsd.edu

Click here for more information and eligibility requirements.

HIV CANCER


AMC-096: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

 

This phase II trial studies a targeted therapy, recombinant EphB4-HSA fusion protein(EphB4-HSA), in treating persons with Kaposi sarcoma. Recombinant EphB4-HSA fusion protein may block the growth of blood vessels that comprise the cancer, and may also prevent cancer cells from growing. 

Enrollment: now through December 2023.

Contact: Erin Reid, MD egreid@ucsd.edu

Click here for more information and eligibility requirements.

HIV CANCER


 

Antiviral Research Center (AVRC)

To enroll in or get more information about one of these clinical trials at the AVRC, please call the Screening Coordinator at (619) 543-3740 or email Marvin Hanashiro at mhanashiro@health.ucsd.edu

Click here to see a full list of the Antiviral Research Center's currently enrolling studies.


ACTG A5401 (Adapt Out COVID) – This is a master protocol to evaluate the safety and efficacy of investigational agents for the treatment of symptomatic non-hospitalized adults with COVID-19.
Click here for more information and eligibility requirements.
HIV  HIV-NEGATIVE  COVID-19


CTG A5380 – People who recently contracted Hepatitis C (HCV) are often considered to have acute HCV. People with acute HCV have a good chance of being cured of the infection when they are treated with a combination of two drugs within the first 6 months of being infected. This study is being done to see if a shorter course of treatment will be effective if started early in the infection (Step 1). In case of failure with this shorter course of treatment, a longer and different treatment regimen for HCV will be offered (Step 2).
Click here for more information and eligibility requirements. 
HEPATITIS C

ACTG A5321 (AHRC) – Studying differences and changes over time in HIV reservoirs (groups of HIV-infected cells that 'hide' from anti-HIV medications) and attempting to answer questions about the ways that HIV infection is controlled. This may have to do with a person’s viral load and CD4 count, when they started their anti-HIV medications, and genetic factors.
HIV

ACTG A5357 – This study will see if cabotegravir and VRC01LS (a monoclonal antibody) work well when taken together to keep HIV levels low, and will also evaluate the safety of the drug combination. 
Click here for more information and eligibility requirements.
HIV

ACTG A5359 (LATITUDE) – This study is investigating if Long-Acting (LA) Injectable ART will be more successful for people who are non-adherent to their HIV medications than oral standard of care regimens. The main advantages of LA ART in this population include infrequent dosing and directly observed therapy. A challenge for participants is that, to be eligible to receive LA ART, they will need to attain virologic suppression through adherence to their SOC oral medications.
Click here for more information and eligibility requirements.
HIV

ACTG A5379 (BEe-HIVe) Vaccination for hepatitis B in individuals living with HIV does not always work, especially in those with impaired immune systems or ability to fight infection. Prevention of hepatitis B in individuals living with HIV has primarily been done by vaccinating with a series of 3 shots given over 6 months. A new vaccine, called HEPLISAV-B, has been approved that may provide a better response than what has currently been used. The researchers will study whether this vaccine will prove to be more effective than the current standard.
Click here for more information and eligibility requirements.
HIV

ACTG 5391 (Do IT) – This research study is trying to find out if people living with HIV who had > 10% weight gain after starting an antiretroviral therapy (ART) regimen that included an INSTI in combination with TAF/FTC (or TAF/3TC) could gain less weight, or maybe lose weight, after switching to an ART regimen containing doravirine (DOR) with either TAF/FTC (or TAF/3TC), or the related medication tenofovir disoproxil fumarate/emtricitabine (TDF/FTC [or TDF/3TC]). DOR is an FDA-approved antiretroviral drug for the treatment of HIV-1 and a member of the non-nucleoside reverse transcriptase inhibitor (NNRTI) medication class. In multiple studies, DOR was shown to be just as effective as INSTI medications for treating HIV.
Click here for more information and eligibility requirements.
HIV

INSTACARE- People with HIV who are out of care are at greater risk of transmitting HIV compared to people on HIV treatment with suppressed levels of virus. To date, there are no interventions that have been shown to successfully link this "out of care" population back into care and successfully maintain viral suppression. This study will test a strategy of providing immediate HIV therapy, intensive linkage support services, and a randomized behavioral intervention.
Click here for more information and eligibility requirements
HIV

LAST GIFT- People at the end of their lives often have a unique perspective on life, death and altruism, and may hold the keys to curing HIV. This study takes the next steps in finding a cure for HIV by understanding how reservoirs are distributed throughout the body.
Click here for more information and eligibility requirements.
HIV

THERAPY FOR CHRONIC PAIN – We want to understand chronic pain in persons aging with HIV and develop treatments to help manage pain.
Click here for more information and eligibility requirements.
HIV

SUBVERT (BACTERIAL VAGINOSIS STUDY) – We are looking for healthy women with a current vaginal bacterial infection (also called Bacterial Vaginosis or BV) and a history of at least two previous episodes of BV to take part in a study of a vaginal product called TOL-463 vaginal insert. TOL-463 is a non-azole vaginal anti-infective drug that may be used for suppression of recurrent BV in women.
Click here for more information and eligibility requirements.
HIV-NEGATIVE  SEXUAL HEALTH


HIV Neurobehavioral Research Program (HNRP)

To enroll in or get more information about research studies at the HNRP, please call (619) 543-5000 and ask to speak with a research recruiter. 

You may be eligible to participate if you:
are at least 18 years old
are HIV+ or HIV- (do not have HIV)
do or do not have a history of substance use

For participating you will receive:
Monetary compensation
Lab results (at no cost to you)
Medical and psychological test results (upon request at no cost to you)

*All information obtained during the study is kept strictly confidential.


iSTEP - an mHealth Physical Activity and Diet Intervention for Persons With HIV

 

Summary: HIV is associated with a pattern of neurocognitive deficits, metabolic dysfunction, and an elevated risk for cardiovascular disease (CVD), phenomena that remain untreated despite the use of medications to control the disease. This proposal will examine the effect of a personalized, automated, interactive mobile phone text message intervention (iSTEP) designed to increase moderate physical activity (PA), decrease sedentary behavior (SB), and promote a healthy Mediterranean-style diet (MedDiet) in persons living with HIV (PLWH). The investigators propose that participants who receive the iSTEP intervention will increase the amount of physical activity, improve their diet, show a reduction in risk factors for CVD, and exhibit improved neurocognitive performance.

Click here for more information and eligibility requirements

HIV


DETECT: A novel device to assess how HIV affects neurocognitive decline and postural instability in older adults at risk for Alzheimer's Disease

 

This is a research study to determine if a brief virtual reality (VR) assessment among older adults living with HIV can help us better screen for changes in cognition and balance.

Click here to download information on this study

Email hnrprecruitment@ucsd.edu for more information or if you are interested in enrolling

HIV


Biomarkers of Resilience and injury related to HIV and Methamphetamine (BRIHM)

This project will look at METH and HIV-associated biomarker signatures of CNS injury and resilience and will translate them to the clinical environment.

Click here to download information on this study

Email hnrprecruitment@ucsd.edu for more information or if you are interested in enrolling

HIV


Cross-species studies of smoking effects on cognition and neuroinflammation in HIV

This study will examine how smoking affects people living with HIV, specifically the function and performance of the brain.

Click here to download information on this study

Email: hnrprecruitment@ucsd.edu for more information or if you are interested in enrolling

HIV


Mother Child Adolescent Program (MCAP)

To enroll or get more information about one of these IMPACT studies at MCAP, please email Study Coordinator: Alejandra Leon at a5leon@health.ucsd.edu


MPAACT 2015: Very Early Intensive Treatment of HIV-Infected Infants to Achieve HIV Remission

The study will explore the effects of early intensive antiretroviral therapy (ART) on achieving HIV remission (HIV RNA below the limit of detection of the assay) among HIV-infected infants.

Click here for more information and eligibility requirements

HIV INFANTS


IMPAACT 2026: Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum

This study will evaluate the pharmacokinetic (PK) properties of antiretroviral (ARV) and anti-tuberculosis (TB) drugs administered during pregnancy and postpartum.

Click here for more information and eligibility requirements

HIV  PREGNANT


MPAACT 2017: More Options for Children and Adolescents (MOCHA): Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in HIV-Infected Children and Adolescents

The purpose of this study is to determine the dosage for oral and IM Cabotegravir LA and IM Rilpiverine LA and evaluate the safety, acceptability, tolerability, and pharmacokinetics of oral and long-acting injectable cabotegravir and long-acting injectable rilpivirine in virologically suppressed HIV-infected children and adolescents.

Click here for more information and eligibility requirements.

HIV  CHILDREN 12-17


Owen Clinic

Check back soon for clinical trial updates for Owen Clinic.


 

 

 

 

Site last updated 10/7/2021